GLOBAL MULTIPLEX ASSAY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Market News

Recent Developments:

New product launches & approvals:

In May 2022, Vela Diagnostics, a biotechnology company, announced the launch of PathoKey MP UTI ID and AMR PCR Test for research use only. This multiplex PCR-based test allows for the in-vitro detection and differentiation of 14 pathogens that cause urinary tract infections (UTI), as well as 14 antimicrobial resistance (AMR) genes encoding resistance to five antibiotics.

In May 2022, Sansure Biotech Inc., a biotechnology company, announced the launch of the Six Respiratory Pathogens Multiplex Nucleic Acid Diagnostic Kit (Multiplex PCR-Fluorescence Probing) developed by Sansure Biotech Inc., was approved for marketing (GXZZ 20223400597). It is the first domestic test reagent based on multiplex fluorescence PCR technology to detect six common bacteria in a single tube.

In November 2020, QIAGEN, a biotechnology company, announced the European launch of the NeuMoDxFlu A-B/RSV/SARS-CoV-2 Vantage Test that will help healthcare professionals quickly identify and differentiate between patients with common seasonal respiratory infections and COVID-19. With the Northern Hemisphere in the grip of flu season, this multiplex polymerase chain reaction (PCR) test detects and differentiates influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes. These viruses produce similar respiratory symptoms, making it essential to provide differential diagnosis among them for patient treatment and management decisions, especially during the COVID-19 pandemic.

Acquisition, collaboration and partnerships:

In June 2023, Bio-Techne Corporation, a global life sciences company, acquired Lunaphore, Inc., a leading developer of fully automated spatial biology solutions, to support the development of diagnostic tools and streamline clinical trials, and ultimately improve patient outcomes

In May 2022, CellCarta, a leading global provider of precision medicine laboratory services, announced the acquisition of the commercial rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics testing solutions. Precision Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry clients.

In April 2021, DiaSorin S.p.A., a global leader in the In Vitro Diagnostic (IVD) field, announced the acquisition of Luminex Corporation, a leader in multiplexing technology. The acquisition will broaden DiaSorin S.p.A.,'s positioning in the molecular diagnostics space and strengthen its existing value proposition in line with its strategic priorities. Through this acquisition, DiaSorin S.p.A gained access to Luminex Corporation’s molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the U.S.